MSFT 435.0 0.7061% AAPL 230.65 -1.2924% NVDA 139.965 -0.9097% GOOGL 176.965 4.2934% GOOG 178.65 4.3882% AMZN 193.73 1.5197% META 594.31 0.1736% AVGO 177.28 -1.0935% TSLA 262.2401 1.0481% TSM 195.14 -0.914% LLY 831.501 -7.977% V 291.3 3.3418% JPM 224.685 0.8008% UNH 564.77 0.4696% NVO 113.15 1.0448% WMT 81.58 -0.1469% LVMUY 134.2 -1.4033% XOM 117.0342 -0.2096% LVMHF 670.0 -1.3008% MA 513.51 1.4281%

Burzynski Research

Healthcare US BZYR

0.036USD
-(-%)

Last update at 2024-10-29T20:00:00Z

Day Range

0.040.04
LowHigh

52 Week Range

0.030.16
LowHigh

Fundamentals

  • Previous Close 0.04
  • Market Cap7.10M
  • Volume5054
  • P/E Ratio-
  • Dividend Yield0.87%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.01

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-02-28 2022-02-28 2021-02-28 2020-02-29 2019-02-28
Type yearly yearly yearly yearly yearly
Date 2023-02-28 2022-02-28 2021-02-28 2020-02-29 2019-02-28
Income before tax -0.91629M -0.97666M -1.20400M -1.63448M -1.63772M
Minority interest - - - - -
Net income -0.91629M -0.97666M -1.20400M -1.63448M -1.63772M
Selling general administrative 0.20M 0.22M 0.28M 0.43M 0.49M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation - - - - -
Ebit - -0.97666M -1.30177M -1.63498M -1.63772M
Ebitda -0.91629M -0.97666M -1.30177M -1.63498M -1.63772M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -0.91629M -0.97666M -1.30177M -1.63498M -1.63772M
Other operating expenses 0.92M 0.98M 1.30M 1.63M 1.64M
Interest expense - 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M - 0.00000M
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.09777M -0.00050M -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 0.92M 0.98M 1.30M 1.63M 1.64M
Cost of revenue - - - - -
Total other income expense net - - 0.10M 0.00050M -
Discontinued operations - - - - -
Net income from continuing ops -0.91629M -0.97666M -1.20400M -1.63448M -1.63772M
Net income applicable to common shares - -0.97666M -1.20400M -1.63448M -1.63772M
Preferred stock and other adjustments - - - - -
Breakdown 2023-02-28 2022-02-28 2021-02-28 2020-02-29 2019-02-28
Type yearly yearly yearly yearly yearly
Date 2023-02-28 2022-02-28 2021-02-28 2020-02-29 2019-02-28
Total assets 0.00193M 0.00466M 0.00096M 0.02M 0.02M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.00100M 0.00128M 0.00089M 0.02M 0.02M
Total liab 0.02M 0.00346M 0.05M 0.17M 0.21M
Total stockholder equity -0.01373M 0.00121M -0.04584M -0.15259M -0.18665M
Deferred long term liab - - - - -
Other current liab 0.00309M 0.00346M 0.01M 0.11M 0.11M
Common stock 0.13M 0.13M 0.13M 0.13M 0.13M
Capital stock 0.13M 0.13M 0.13M 0.13M 0.13M
Retained earnings -126.75477M -125.83848M -124.86183M -123.65783M -122.02335M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.00093M 0.00338M 0.00006M 0.00016M 0.00071M
Cash and equivalents - - - - -
Total current liabilities 0.02M 0.00346M 0.05M 0.17M 0.21M
Current deferred revenue - - - - -
Net debt -0.00093M -0.00338M -0.00006M -0.00016M -0.00071M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 126.61M 125.71M 124.68M 123.37M 121.71M
Property plant equipment - - - - -
Total current assets 0.00193M 0.00466M 0.00096M 0.02M 0.02M
Long term investments - - - - -
Net tangible assets - 0.00121M -0.04584M -0.15259M -0.18665M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.01M 0.00000M 0.03M 0.06M 0.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.00000M 0.00000M
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2023-02-28 2022-02-28 2021-02-28 2020-02-29 2019-02-28
Type yearly yearly yearly yearly yearly
Date 2023-02-28 2022-02-28 2021-02-28 2020-02-29 2019-02-28
Investments - - - - -
Change to liabilities - -0.03251M -0.02829M -0.04026M 0.06M
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities 0.25M 0.33M 0.39M 0.53M 0.48M
Change to operating activities - -0.01122M 0.02M 0.00565M 0.02M
Net income -0.91629M -0.97666M -1.20400M -1.63448M -1.63772M
Change in cash -0.00245M 0.00332M -0.00010M -0.00055M 0.00020M
Begin period cash flow 0.00338M 0.00006M 0.00016M 0.00071M 0.00051M
End period cash flow 0.00093M 0.00338M 0.00006M 0.00016M 0.00071M
Total cash from operating activities -0.24952M -0.32510M -0.39437M -0.53011M -0.47752M
Issuance of capital stock - - - - -
Depreciation - - - - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.25M 0.33M 0.39M 0.53M 0.48M
Change to netincome - 0.70M 0.82M 1.14M 1.08M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.01M -0.04373M -0.00907M -0.03461M 0.08M
Stock based compensation - - - - -
Other non cash items 0.65M 0.70M 0.82M 1.14M 1.08M
Free cash flow -0.24952M -0.32510M -0.39437M -0.53011M -0.47752M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BZYR
Burzynski Research
- -% 0.04 - - - 2190.81 -5.7356
NVO
Novo Nordisk A/S
1.17 1.04% 113.15 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
1.95 1.76% 112.70 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
3.92 0.83% 474.27 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
-1.92 0.21% 925.41 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to the treatment of various cancers. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. Burzynski Research Institute, Inc. was incorporated in 1984 and is headquartered in Houston, Texas.

Burzynski Research

9432 Katy Freeway, Houston, TX, United States, 77055

Key Executives

Name Title Year Born
Dr. Stanislaw R. Burzynski Chairman, CEO & Pres 1943
Mr. Patryk P. Goscianski Treasurer & Sec. 1978

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.